ME03326B - C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze - Google Patents

C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze

Info

Publication number
ME03326B
ME03326B MEP-2019-45A MEP201945A ME03326B ME 03326 B ME03326 B ME 03326B ME P201945 A MEP201945 A ME P201945A ME 03326 B ME03326 B ME 03326B
Authority
ME
Montenegro
Prior art keywords
deficiency
procedures
prevention
treatment
disorders related
Prior art date
Application number
MEP-2019-45A
Other languages
German (de)
English (en)
French (fr)
Inventor
Cynthia Gallagher
Stephen Ruddy
Mark Cornell Manning
Original Assignee
Shire Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03326(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc
Publication of ME03326B publication Critical patent/ME03326B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MEP-2019-45A 2013-03-15 2014-03-17 C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze ME03326B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
EP17177676.8A EP3290046B1 (en) 2013-03-15 2014-03-17 C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Publications (1)

Publication Number Publication Date
ME03326B true ME03326B (me) 2019-10-20

Family

ID=51538486

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2017-182A ME02865B (me) 2013-03-15 2014-03-17 C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
MEP-2019-45A ME03326B (me) 2013-03-15 2014-03-17 C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2017-182A ME02865B (me) 2013-03-15 2014-03-17 C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)

Country Status (30)

Country Link
US (9) US9616111B2 (me)
EP (3) EP3508213A1 (me)
JP (9) JP6184581B2 (me)
KR (4) KR102430453B1 (me)
CN (2) CN111529708A (me)
AU (3) AU2014232912A1 (me)
BR (1) BR112015023207A8 (me)
CA (2) CA3054718A1 (me)
CY (2) CY1119419T1 (me)
DE (1) DE202014011208U1 (me)
DK (2) DK2968434T3 (me)
EA (1) EA201591278A1 (me)
ES (2) ES2713004T3 (me)
GB (1) GB2530921B (me)
HK (1) HK1250912B (me)
HR (2) HRP20171269T1 (me)
HU (2) HUE041837T2 (me)
IL (2) IL241549B (me)
LT (2) LT2968434T (me)
ME (2) ME02865B (me)
MX (3) MX389449B (me)
PL (2) PL3290046T3 (me)
PT (2) PT3290046T (me)
RS (2) RS56285B1 (me)
SG (2) SG10201707598QA (me)
SI (2) SI3290046T1 (me)
SM (2) SMT201900141T1 (me)
TR (1) TR201900319T4 (me)
WO (1) WO2014145519A2 (me)
ZA (3) ZA201507604B (me)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102430453B1 (ko) 2013-03-15 2022-08-05 바이로파마 바이오로직스 엘엘씨 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
MX378834B (es) * 2013-11-22 2025-03-11 Takeda Pharmaceuticals Co El uso de un inhibidor de c1-esterasa para el tratamiento del rechazo mediado por anticuerpos en pacientes con trasplante de órganos.
CN107257683A (zh) * 2015-02-20 2017-10-17 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
CN108025047B (zh) * 2015-05-28 2021-11-19 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
ES2927271T3 (es) 2015-11-19 2022-11-03 Takeda Pharmaceuticals Co Inhibidor de esterasa C1 humana recombinante y usos del mismo
AU2017305856B2 (en) 2016-08-05 2024-09-12 Csl Behring Gmbh Pharmaceutical formulations of C1 esterase inhibitor
AU2017316513A1 (en) * 2016-08-23 2019-03-28 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
CN110769848A (zh) * 2017-05-16 2020-02-07 瑞士奥克特珐玛公司 C1-酯酶抑制剂制剂
AU2019226355A1 (en) 2018-02-28 2020-09-17 Pharming Intellectual Property B.V. Treatment and prevention of pre-eclampsia
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
TWI832868B (zh) 2018-06-22 2024-02-21 日商順天生化股份有限公司 用於誘發感染性免疫耐受之組合物
AU2019288635A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
KR20250096878A (ko) 2018-06-22 2025-06-27 가부시키가이샤 준텐 바이오 복합 상태를 갖는 세포 혼합물을 이용한, 면역 관용을 유도하는 항체 및 유도된 림프구, 또는 유도된 림프구를 이용하는 세포 치료제 및 치료법
US20230041642A1 (en) * 2019-12-16 2023-02-09 Nipro Corporation Aggregation Inhibitory Agent and Medical Composition and Medical Device Including Same
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
CA3225079A1 (en) 2021-07-09 2023-01-12 Bruno Giannetti Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
PT716611E (pt) * 1993-09-01 2002-06-28 Sanquin Bloedvoorziening Metodo para reduzir a lesao do miocardio durante um enfarte do miocardio agudo
AU1042597A (en) 1995-12-18 1997-07-14 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
WO2001057079A2 (en) 2000-01-31 2001-08-09 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2003300781A1 (en) 2002-09-25 2004-05-04 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
DK1626736T3 (da) 2003-05-16 2020-09-28 Pharming Intellectual Property B V C1-inhibitor med kort halveringstid til midlertidig behandling
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP1893227A2 (en) 2005-06-06 2008-03-05 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
ES2611608T3 (es) 2005-10-21 2017-05-09 Catalyst Biosciences, Inc. Proteasas modificadas que inhiben la activación del complemento
ES2369522T3 (es) * 2005-12-21 2011-12-01 Pharming Intellectual Property B.V. Uso de un inhibidor c1 para la prevención de lesiones por isquemia-reperfusión.
DK2380587T3 (en) 2005-12-21 2017-12-04 Pharming Intellectual Property B V Use of a C1 inhibitor to prevent ischemia-reperfusion injury
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
KR101629702B1 (ko) 2007-02-12 2016-06-13 체에스엘 베링 게엠베하 카잘-형 세린 프로테아제 억제제의 치료학적 적용
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20150080038A (ko) 2007-11-30 2015-07-08 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
CN106390117A (zh) 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
US20130085111A1 (en) * 2010-03-18 2013-04-04 Thrombolytic Science, Llc Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
WO2013041677A1 (en) 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor
CN104080474B (zh) * 2011-12-22 2016-04-27 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
EP2825205A1 (en) 2012-03-16 2015-01-21 Belrose Pharma Inc. Polymeric conjugates of c1-inhibitors
CA2902841A1 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
KR102430453B1 (ko) * 2013-03-15 2022-08-05 바이로파마 바이오로직스 엘엘씨 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック

Also Published As

Publication number Publication date
ES2713004T3 (es) 2019-05-17
NZ751555A (en) 2021-07-30
KR20210021146A (ko) 2021-02-24
MX2015011281A (es) 2016-03-03
AU2018229558A1 (en) 2018-10-04
ME02865B (me) 2018-04-20
CA2904543C (en) 2019-10-08
KR20150135242A (ko) 2015-12-02
HK1250912B (en) 2020-01-10
MX2020004724A (es) 2022-01-18
ZA201507604B (en) 2018-05-30
SMT201900141T1 (it) 2019-05-10
ZA201706929B (en) 2019-05-29
SI3290046T1 (sl) 2019-04-30
CY1119419T1 (el) 2018-03-07
SMT201700415T1 (it) 2017-11-15
CY1121653T1 (el) 2020-07-31
CN111529708A (zh) 2020-08-14
US20190160158A1 (en) 2019-05-30
GB2530921B (en) 2017-09-20
US20180085441A1 (en) 2018-03-29
JP2016516073A (ja) 2016-06-02
JP2018119001A (ja) 2018-08-02
KR20220070049A (ko) 2022-05-27
JP6473536B2 (ja) 2019-02-20
US11364288B2 (en) 2022-06-21
ES2639833T3 (es) 2017-10-30
EP2968434A2 (en) 2016-01-20
HK1220403A1 (en) 2017-05-05
JP2018119000A (ja) 2018-08-02
JP2017105847A (ja) 2017-06-15
AU2018229558B2 (en) 2020-03-05
BR112015023207A8 (pt) 2018-01-23
AU2020203183A1 (en) 2020-06-04
AU2014232912A1 (en) 2015-09-03
HRP20190270T1 (hr) 2019-04-05
AU2020203183B2 (en) 2022-06-02
HUE036224T2 (hu) 2018-06-28
PT3290046T (pt) 2019-02-18
US9616111B2 (en) 2017-04-11
PL3290046T3 (pl) 2019-05-31
EP2968434B1 (en) 2017-06-28
EP2968434A4 (en) 2016-03-02
WO2014145519A2 (en) 2014-09-18
US20190160157A1 (en) 2019-05-30
MX389449B (es) 2025-03-20
SG11201507616VA (en) 2015-10-29
JP2019073544A (ja) 2019-05-16
EP3290046A1 (en) 2018-03-07
SI2968434T1 (sl) 2017-11-30
SG10201707598QA (en) 2017-10-30
KR102430453B1 (ko) 2022-08-05
CA3054718A1 (en) 2014-09-18
CN105517559A (zh) 2016-04-20
IL241549B (en) 2020-08-31
MX2021011946A (es) 2021-11-17
US20160015795A1 (en) 2016-01-21
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
US20180153972A1 (en) 2018-06-07
BR112015023207A2 (pt) 2017-11-21
HUE041837T2 (hu) 2019-05-28
RS58351B1 (sr) 2019-03-29
US20180110844A1 (en) 2018-04-26
JP6184581B2 (ja) 2017-08-23
US10080788B2 (en) 2018-09-25
JP2021088599A (ja) 2021-06-10
US20170224788A1 (en) 2017-08-10
DK2968434T3 (en) 2017-09-11
KR20210129267A (ko) 2021-10-27
US20200261556A1 (en) 2020-08-20
TR201900319T4 (tr) 2019-02-21
JP2019073546A (ja) 2019-05-16
ZA201806793B (en) 2020-01-29
IL276153B (en) 2022-06-01
JP2019073545A (ja) 2019-05-16
US11534482B2 (en) 2022-12-27
LT2968434T (lt) 2017-09-25
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
JP6877472B2 (ja) 2021-05-26
EA201591278A1 (ru) 2016-03-31
JP6422520B2 (ja) 2018-11-14
WO2014145519A3 (en) 2014-12-31
GB2530921A (en) 2016-04-06
IL276153A (en) 2020-09-30
PL2968434T3 (pl) 2018-01-31
HRP20171269T1 (hr) 2017-11-03
EP3508213A1 (en) 2019-07-10
PT2968434T (pt) 2017-09-18
JP6473535B2 (ja) 2019-02-20
LT3290046T (lt) 2019-03-12
CA2904543A1 (en) 2014-09-18
KR102579789B1 (ko) 2023-09-15
JP6473534B2 (ja) 2019-02-20
DK3290046T3 (en) 2019-03-18
DE202014011208U1 (de) 2018-08-23
JP2018119002A (ja) 2018-08-02
GB201519921D0 (en) 2015-12-23
JP6877471B2 (ja) 2021-05-26
EP3290046B1 (en) 2019-01-02
JP6877470B2 (ja) 2021-05-26
MX373965B (es) 2020-07-13
US10105423B2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
ME03326B (me) C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
EP2911669C0 (en) SYNERGIC COMBINATION OF IMMUNOLOGICAL INHIBITORS FOR THE TREATMENT OF CANCER
DK3444342T3 (da) Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
HRP20181734T1 (hr) Procjena i liječenje poremećaja posredovanih bradikininom
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
DK2794604T3 (da) Hidtil ukendte dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af inflammatoriske lidelse
EP2968133A4 (en) TOPICAL COMPOSITIONS AND METHOD FOR THE TREATMENT OF TOPICAL DISEASES
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK3685848T3 (da) Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
EP4088724C0 (en) ACETYLCHOLINESTERASE INHIBITORS FOR THE ORAL TREATMENT OF DERMATOLOGICAL CONDITIONS
PL3189074T3 (pl) Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom
IL246269B (en) Compositions and methods for treating fatty tissue buildup
IL284347A (en) Geranium oil and constituents thereof for treatment of neurodegenerative diseases
EP3632467C0 (en) COMPLEMENT FACTOR H INHIBITORS
HRP20180687T1 (hr) Kompozicije i metode za liječenje celijakije spru
EP2825185C0 (en) NEW METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
DK2892556T3 (da) Sammensætninger og fremgangsmåder til behandling af sygdomme
EP3386507A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF STOMACH DISEASES
EP2968084A4 (en) COMPOSITIONS FOR THE TREATMENT OF XEROSTOMY AND DENTAL TREATMENT
LT2734544T (lt) Su poliomavirusu susijusios patologijos slopinimo metodai ir kompozicijos
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna